With respect to the activation of PKC, preclinical evidence in the diabetic rat heart has shown that administration of PKC inhibitors is protective against diabetic cardiomyopathy.105, 106 This is pertinent as insulin resistance leads to the cellular depletion of glucose transporters, GLUT1 and GLUT4, initiating a switch to fatty acid oxidation that ultimately results in reduced cardiac performance. This evidence concerns the gene PRRT2 and diabetic cardiomyopathy.